Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679133 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00679133 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 47 participants.
The verdict
NCT00679133, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.
Interventions
- DRUG MGCD265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679133
The ClinicalTrials.gov registry entry for NCT00679133 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGCD265 is the first listed.
NCT00679133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00679133 about?
NCT00679133 is a clinical study titled "Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies". In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.
What is the current status of trial NCT00679133?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2008-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00679133?
The interventions under investigation include: MGCD265 (DRUG).
Who is sponsoring clinical trial NCT00679133?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.